About us

Scantox A/S is a Scandinavian GLP ("Good Laboratory Practice") accredited preclinical contract research company ("CRO") with primary focus on pharmacology and regulatory toxicology. With its many years of scientific experience, Scantox is today a trusted partner for companies working with product development within the pharmaceutical and biotechnology industries, as well as within the development of new medical devices.

The core competencies of Scantox range from handling test subjects and in-life examinations, to histopathology, where tissue slides are produced and evaluated by an experienced team of pathologists. In addition, all types of standard clinical pathology analyses, as well as specialized biomarkers, are carried out according to international toxicological guidelines. Dose formulation analysis, bioanalysis and safety pharmacology testing are also part of Scantox' specialties.

The preclinical in vivo research carried out by Scantox enables customers to continue the development of their medicine or medical device, based on scientific research results produced to the strictest quality requirements.

Everyone at Scantox works from a strong shared vision to improve human health, and all processes in the company are based on dedication and a common mission with a clear purpose in mind.

Scantox was founded in 1977 and is today owned by the Nordic investment company Impilo. The company is headquartered in Denmark with subsidiaries in Denmark, Sweden, UK and Austria.